Current and future modalities for functional renal replacement

G. E. Amiel, A. Atala

Research output: Contribution to journalArticle

68 Scopus citations

Abstract

Approximately 310 000 Americans suffer from end-stage renal disease, with more than 70 000 new cases reported each year. Advances in immunosuppressive therapy for transplanted patients, in addition to the refined care of patients who are dependent on dialysis, have led to an improved survival for patients with renal failure. Structural, molecular, and pharmacologic developments continue to enhance the efficacy and safety of dialysis in the future. In addition, progressive improvements in the past 2 decades in organ transplantation, a greater insight into the immunobiology of graft rejection, and better surgical and medical management have resulted in improved outcomes. Although renal xenotransplantation is still in its early stages of development, additional research is leading this technology forward. Recent successes in harvesting and expanding renal cells in vitro and the development of biologically active synthetic materials allow for the creation of three-dimensional functioning renal units, which, in the future, may be applied ex vivo or in vivo for partial or full replacement of kidney function.

Original languageEnglish (US)
Pages (from-to)235-246
Number of pages12
JournalUrologic Clinics of North America
Volume26
Issue number1
DOIs
StatePublished - Jan 1 1999

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Current and future modalities for functional renal replacement'. Together they form a unique fingerprint.

  • Cite this